Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Recalcitrant Non-infectious Uveitis
NCT06085079Phase 4Unknown
- Sponsor
- Massachusetts Eye and Ear
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ixekizumab in uveitis (2 arms), sponsored by Massachusetts Eye and Ear. Primary endpoint: Clinical response at 10 weeks. Status: unknown.
02
Drugs
ixekizumab
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT06085079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085079.